NCT06600841View on ClinicalTrials.gov

Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

October 1, 2028

Conditions

Platinum-resistant Ovarian Cancer (PROC)Immunotherapy

Interventions

DRUG

Immunotherapy（Adebrelimab）

Adebrelimab plus non-platinum chemotherapy（Liposomal doxorubicin/Gemcitabine/ or nab-paclitaxel）and fluzoparib induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib.

DRUG

immunotherapy（Adebrelimab）

anti-PD-L1

Trial Locations (1)

350014

Fujian Cancer Hospital, Fuzhou

All Listed Sponsors

collaborator

Fujian Provincial Hospital

OTHER

lead

Fujian Cancer Hospital

OTHER_GOV

NCT06600841 - Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer | Biotech Hunter | Biotech Hunter